本福提胺通过调节神经炎症,氧化应激和微质细胞来改善大鼠中链毒素诱导的阿尔茨海默病
Camila A E F Cardinali1, Yandara A Martins2, Ruan C M Moraes2,3
1Departamento de Fisiologia E Biofisica, Universidade de Sao Paulo, Av Professor Lineu Prestes 2415, Sao Paulo, 05508-000, Brazil. camila.cardinali@icb.usp.br.
Molecular neurobiology
|March 4, 2025
概括
本福胺 (BFT) 降低了阿尔茨海默氏症患者的炎症和氧化应激.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特征是认知能力下降.
- 涉及质细胞 (小质细胞,星球细胞) 的神经炎症是AD病原体的核心.
- 炎症和氧化应激有助于神经元损伤和神经发生障碍在AD.
研究的目的:
- 评估本福胺 (BFT) 在偶发性阿尔茨海默氏症样疾病模型中的神经保护作用.
- 研究BFT对微质形态,炎症和氧化应激的影响.
- 探索潜在的机制,包括Nrf-2通路的激活.
主要方法:
- 通过在动物中注射脑内链毒素 (STZ) 诱导了一种零星的类似阿尔茨海默氏症的疾病模型.
- 服用本福胺 (BFT) 剂量为150mg/kg,持续7天.
- 评估了海马体炎症,内腔皮层氧化损伤,微质形态和Nrf-2通路激活.
主要成果:
- 服用BFT补充剂显著降低了海马体炎症.
- BFT提供了对内皮层氧化损伤的保护.
- BFT激活了Nrf-2通路并增强了抗氧化酶表达 (SOD1,CAT).
结论:
- 本福胺 (BFT) 在阿尔茨海默氏症模型中显示出显著的神经保护作用.
- 通过调节质细胞功能和 redox 稳态,BFT 改善神经炎症和氧化应激.
- Nrf-2通路和抗氧化酶诱导是BFT在AD治疗作用的关键机制.
更多相关视频
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.0K
相关概念视频
01:22Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145
01:26Alzheimer's Disease: Overview
418
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
418